Background

Senescent mesenchymal stromal cells (MSCs) accumulate with age and secrete a SASP that can influence neighboring stem cells. Recent work shows aged MSCs exhibit downregulated HOX genes, correlating with loss of stemness and osteogenic potential [1]. Senolytic agents such as quercetin and ABT-263 clear these cells and modestly improve proliferation and differentiation [2],[3], yet they fail to reset epigenetic age or telomere length, suggesting they address superficial phenotypes. Meanwhile, adult MSCs retain embryonic positional information via stable HOX codes [4]. Whether senescent MSCs actively preserve this positional memory through paracrine signaling remains untested.

Hypothesis

We hypothesize that senescent MSCs function as transient chaperones of tissue positional identity by secreting specific SASP components (e.g., IGFBP7, WNT5A, and TGF‑β1) that sustain HOX gene expression in adjacent mesenchymal progenitors. Acute removal of these cells with senolytics will therefore cause a rapid, reversible decline in HOX transcript levels and impair lineage‑restricted differentiation, which can be rescued by replenishing the identified SASP factors.

Predictions

1. HOX downregulation post‑senolysis: In vitro cultures of aged human MSCs treated with quercetin + ABT‑263 will show a ≥30 % reduction in HOXA9, HOXA10, and HOXC8 mRNA within 24 h, preceding any change in proliferation.
2. SASP‑mediated rescue: Conditioned media from senescent MSCs (or recombinant IGFBP7 + WNT5A + TGF‑β1) will restore HOX expression to baseline levels in senolytic‑treated cultures.
3. Functional consequence: Loss of HOX signaling will diminish osteogenic adipogenic bias, measurable by reduced Alizarin Red and Oil‑Red‑O staining, which is rescued by SASP supplementation.
4. In‑vivo relevance: Local senolytic injection into aged mouse tibial marrow will transiently decrease Hoxa10 expression in lineage‑negative MSCs (sorted by CD45‑Ter119‑CD31‑Sca1+CD200+), accompanied by a short‑term dip in bone formation rate, reversible by intra‑osseous delivery of the SASP cocktail.

Experimental Design

In vitro: Isolate MSCs from donors >65 years, induce senescence via low‑dose doxorubicin, confirm SA‑β‑gal and p16^INK4a^ up. Treat with senolytic cocktail (1 µM quercetin + 0.5 µM ABT‑263) or vehicle. Harvest RNA at 0, 6, 12, 24 h for qPCR of HOX genes and SASP factors. Parallel wells receive conditioned media from untreated senescent MSCs or recombinant protein mix. Differentiate toward osteoblast/adipocyte lineages and quantify matrix deposition.

In vivo: Use 20‑month‑old C57BL/6 mice. Inject clodronate liposomes to deplete macrophages (control for off‑target effects), then inject tibial marrow with senolytic or PBS. Harvest MSCs at 6 h, 24 h, 72 h for FACS sorting and Hoxa10 qPCR. A separate cohort receives local SASP protein injection immediately after senolytic. Histomorphometry assesses osteoblast surface and mineral apposition rate.

Potential Outcomes and Interpretation

• If HOX transcripts fall rapidly after senolysis and are rescued by SASP, the data support a chaperone role: senescent MSCs actively maintain positional identity via a secreted signaling hub.
• If HOX expression remains unchanged despite senescent cell clearance, the chaperone model is refuted; senescent MSCs are likely passengers, and any functional improvements from senolytics arise from removing deleterious SASP components rather than losing a supportive signal.
• A transient dip followed by rebound would indicate compensatory mechanisms, suggesting the niche can adapt but that senescent cells provide a short‑term buffering function.

This framework directly tests the 'witness' analogy by linking senescent cell clearance to measurable changes in HOX‑driven positional memory, offering a falsifiable path to resolve whether we are indeed removing a critical tissue chaperone when we clear senescent MSCs.